Therapeutics that Unlock
Survival for Cancer Patients
tumor microenvironment
The tumor microenvironment
is like a wound that never heals
The challenge of the tumor microenvironment
  • Tumor cells manipulate the innate immune system into fostering cancer proliferation and progression.
  • Cooperative signalling produces an immunosuppressive milieu that impedes the adaptive immune response.
Cancer research has focused so intently on the genomics of tumors that the DNA of the immune system has largely been overlooked as a source of oncology drug targets.
Germline biomarkers of cancer patient survival
  • Prognostic analysis antithetically highlights germline genomics as 10x more important in predicting survival than tumor multi-omics
  • Novel immunomodulatory targets discovered in multiple indications: NSCLC, colorectal, bladder, and melanoma.
Dana-Farber logo
AdventHealth logo
scientific posters
KeyBio research presented at
AACR 2024 and ASCO 2023
KeyBio is developing immuno-oncology therapeutics that mimic immunoregulatory germline genomic mutations observed in patients that survive cancer.
Genomic biomarker discovery capabilities
kinase cascade
Discover Targets
Identify pathways that drive molecular subtypes of disease progression by learning from longitudinal, clinicogenomic cohorts.
Therapeutic (Tx)
immune checkpoint drug
Stratify Trials
Optimize clinical trials for safety and efficacy with patient selection strategies that incorporate MoA-related genomic biomarkers.
Companion Diagnostic (CDx)
Built on a deep learning technology platform
  • AI Quality Control (AIQC) is our open source Python framework for systematic deep learning
  • Rapidly train & evaluate neural networks on multi-modal data without sacrificing scientific rigor
  • Designed to automate reproducibility, explainablity, & data integrity for audits
Documentation
Presentation
track experiments
compare models
run simulations
►
◀
Bult-in UI for real-time experiment tracking
OncoGerm: biomarker discovery engine
analytical workflow
More realistic modeling of systems biology
Association Studies are Univariate
Traditionally, each mutation is tested for correlation with the health outcome one-by-one. Lack of interaction produces many disparate hypotheses. No patient-specific predictions, only population-wide statistics.
gwas simplicity
v.s.
neural network topology
Neural Networks are Multivariate
Genes interact with each other within a unified algorithm. Predict patient-specific health outcomes. Prioritize more realistic population-wide biomarkers via permutation. Incorportate multi-modal data.
Rather than chasing the latest academic biostatistical tools, why not embrace the flexibility and power of deep learning?
Guidance from scientific & strategic experts
Keith Flaherty
Keith Flaherty, MD
Founder (Scorpion Tx, Loxo@Lilly, Strata Oncology), Director Clinical Research - MGH, Professor - Harvard Med
Keith is a pioneer of therapeutic cancer biomarkers. He is an accomplished leader in every sphere of this domain: translational medicine, storied academic research, and has founded multiple therapeutic and diagnostic ventures along the way.
Guru Sonpavde
Guru Sonpavde, MD
Director GU Oncology & Clinical Trials - AdventHealth Cancer Institute, Director Bladder Cancer - DanaFarber, Professor of Medicine
Guru has published and practiced extensively in the field of clinical oncology at multiple cancer institutes. He has served as the principal investigator for several clinical trials, currently directs Advent's phase I program, and is extremely cognizant of the latest developments in the cancer therapeutics industry.
Arvind Ravi
Arvind Ravi, MD, PhD
Physician Scientist, Medical Oncologist, Genomics Researcher:
BWH, Dana-Farber, Broad Institute
Arvind has developed comprehensive expertise across quantitative, experimental, and clinical domains at the highest level of excellence. This gives him the rare ability to not only see the whole picture but also zoom in wherever necessary. His foundational research on the role of miRNA in oncogenesis has refined the known biological mechanisms of this omic.
Alex Fowkes
Alex Fowkes
Pharma R&D Strategy:
Pfizer, WuXi AppTec, WuXiNextCODE
When it comes to the biopharma industry, Alex has seen it all. Having managed R&D, M&A, and commercial strategy at companies ranging from leading pharmaceuticals, to contract research organizations (CROs) and high-growth technology startups - his innate ability to navigate challenging situations with precision is unparalleled.
→ Contact